Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI3046 in Chinese Participants With Overweight or Obesity
NCT07809945Phase 1Recruiting
- Sponsor
- Innovent Biologics
- Start
- Sep 2026
- Primary completion
- Jul 2028
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of IBI3046 in obesity (8 arms), sponsored by Innovent Biologics. Primary endpoints: Number of participants with Adverse Event at Day 225, Change in systolic blood pressure after dosing at Day 225 and 4 more. Started Sep 2026; status: recruiting.
02
Drugs
IBI3046
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07809945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07809945.